Healthtech funding in H1 2020
European Healthtech startup funding raised during H1 2020.
In H1 2020, 200 European Healthtech companies closed 203 funding rounds and raised €2.4B in equity funding (excluding debt and grants), up 14.1% versus H1 2019. UK led by capital raised, and High-Tech Gründerfonds (HTGF) was the most active investor. Data as of 20 Nov 2026.
Equity funding
€2.4B
+14.1% vs H1 2019 · excl. debt & grants
Funding rounds
203
-7.7% vs H1 2019
Companies
200
Top country
UK
Rank among sectors
#5
9.4% of sector funding
Top-10 round share
36.8%
of disclosed capital
Rounds ≥ €100M
2
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, H1 2020 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Jan | €347M | 54 |
| Feb | €365M | 37 |
| Mar | €164M | 18 |
| Apr | €533M | 39 |
| May | €412M | 35 |
| Jun | €612M | 20 |
Top countries
by € raisedHealthtech — top countries by capital, H1 2020 — interactive chart.
Data table
| Healthtech — top countries by capital, H1 2020 | |
|---|---|
| UK | €668M |
| Germany | €482M |
| France | €299M |
| Israel | €287M |
| Sweden | €146M |
| Switzerland | €123M |
| Netherlands | €98M |
| Belgium | €86M |
Stage mix
by € raisedHealthtech — stage mix, H1 2020 — interactive chart.
Data table
| Healthtech — stage mix, H1 2020 | |
|---|---|
| Other | €670M |
| Series B | €486M |
| Series A | €385M |
| Early VC | €340M |
| Series C | €314M |
| Seed | €92M |
| Series D+ | €75M |
| Growth/Late | €51M |
| Grant | €20M |
Exits & M&A
25 Acquisition · 1 Buyout28 exits · €1.2B disclosed.
| Polyplus-Transfection | Acquisition | Feb 2020 | €460M |
| Galecto | Acquisition | Jan 2020 | €398M |
| MaSTherCell | Acquisition | Feb 2020 | €285M |
| Inui Health | Acquisition | Jun 2020 | €8.0M |
| 2CSI | Acquisition | Apr 2020 | €2.1M |
| ApiFix | Acquisition | Apr 2020 | €1.8M |
Top deals
largest disclosed rounds in H1 2020| Company | Stage | Date | Amount |
|---|---|---|---|
| CureVac | Early VC | Jun 2020 | €300M |
| Oxford Nanopore Technologies | Other | Apr 2020 | €124M |
| Compass Pathways | Series B | Apr 2020 | €74M |
| Compugen | Other | Mar 2020 | €68M |
| Cera | Other | Feb 2020 | €65M |
| Verve Therapeutics | Series A | Jun 2020 | €56M |
| Exscientia | Series C | May 2020 | €55M |
| Oxford Nanopore Technologies | Other | May 2020 | €54M |
| Avacta Group | Growth/Late | Apr 2020 | €51M |
| Dynacure | Series C | Feb 2020 | €50M |
| Enterome | Series D+ | Jun 2020 | €46M |
| Doktor.se | Series C | May 2020 | €45M |
| K Health | Series C | Feb 2020 | €44M |
| Robocath | Series C | Apr 2020 | €40M |
| Northsea Therapeutics | Series B | Jan 2020 | €36M |
Top investors
most active in H1 2020, by deal count- High-Tech Gründerfonds (HTGF)4 deals
- Ananda Impact Ventures2 deals
- Business Finland2 deals
- Cathay Innovation2 deals
- IDInvest Partners2 deals
- Kamet Ventures2 deals
- M Ventures2 deals
- Mercia Asset Management2 deals
- MTIP AG2 deals
- NPIF – Mercia Equity Finance2 deals